Skip to content
Zytoprotec GmbH logo — Redefining Healthcare through Innovative Cytoprotection Solu...

Zytoprotec GmbH

Redefining Healthcare through Innovative Cytoprotection Solutions.

Founded 2007 2 employees Series A Total: $2.00M Biopharma, Biotechnology

General Information

Company Name Zytoprotec GmbH
Founded Year 2007
Employees 2
Industries Biopharma, Biotechnology
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with Zytoprotec GmbH. To contact Zytoprotec GmbH, visit zytoprotec.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Zytoprotec GmbH compare?

A PDF of Zytoprotec GmbH and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Zytoprotec GmbH soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Zytoprotec GmbH

Zytoprotec GmbH:

Overview: Zytoprotec, established in 2007 in Austria, is a biotechnology enterprise dedicated to applying leading discoveries in cytoprotection to create innovative treatments for significant diseases. The company was founded by a group of experts with extensive backgrounds in business administration, clinical research, pharmaceutical product development, and both company and patent law.

Focus: Industries: Biopharma, Biotechnology

Recent Investment: Received a €2.00M Series A investment on 29 January 2013 from Baxter International.

Slogan: "Redefining Healthcare through Innovative Cytoprotection Solutions."

Conclusion: Zytoprotec is a promising biotechnology startup with a strong emphasis on innovative treatments and a notable investment backing from Baxter International in 2013.

Business keywords: cytoprotection, innovation, therapeutics, clinical research, pharmaceuticals, disease treatments, Austria, startup, investments, biotech, patent law, business administration, drug development

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series A €2.00M 1
Baxter International
29 Jan 2013

Zytoprotec GmbH Alternatives & Competitors

View All Alternatives
Zytoprotec GmbH vs

Innovative solutions for treating infectious eye diseases with advanced technology and original conc...

Venture round
1 employees
Biopharma, Biotechnology
Zytoprotec GmbH vs

Pioneering breakthrough treatments for central nervous system diseases through innovative gene disco...

Series C
Biopharma, Biotechnology
Zytoprotec GmbH vs
KeifeRx
KeifeRx United States

KeifeRx is a biopharmaceutical company finding disease-modifying treatments for neurodegenerative di...

Series A
7 employees
Biopharma, Biotechnology

FAQ About Zytoprotec GmbH

Redefining Healthcare through Innovative Cytoprotection Solutions.
Zytoprotec GmbH was founded in 2007.
Zytoprotec GmbH operates in Biopharma and Biotechnology. Its work centres on cytoprotection, innovation, therapeutics and clinical research.
Zytoprotec GmbH has approximately 2 employees.
Zytoprotec GmbH has completed 1 funding round, raising a total of $2.00M. The latest funding stage is Series A.
Top alternatives and competitors to Zytoprotec GmbH include Adenovir Pharma AB, AGY Therapeutics, KeifeRx, Apollo Therapeutics, Beyond Air®. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Zytoprotec GmbH and Adenovir Pharma AB are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Zytoprotec GmbH, https://bouncewatch.com/company/zytoprotec, updated 26 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout